Published in Hepatitis Weekly, September 22nd, 2003
According to recent research published in the journal Antimicrobial Agents and Chemotherapy, "the pharmacokinetics of [C-14]viramidine, a prodrug of ribavirin, were studied in rats (30 mg/kg of body weight) and monkeys (10 mg/kg) following intravenous (i.v.) and oral administration."
"The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys. Following i.v. administration, the elimination half-lives were 2.7 hours (h) in rats and 28.9 h in monkeys," reported C.C. Lin and colleagues, Ribapharm...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.